Fresenius SE KGaA (XTER:FRE) Research & Development : €642 Mil (TTM As of Mar. 2025)

View and export this data going back to 1992. Start your Free Trial

What is Fresenius SE KGaA Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Fresenius SE KGaA's Research & Development for the three months ended in Mar. 2025 was €140 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was €642 Mil.

Fresenius SE KGaA Research & Development Historical Data

The historical data trend for Fresenius SE KGaA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius SE KGaA Research & Development Chart

Fresenius SE KGaA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Research & Development

Get a 7-Day Free Trial

751.00

805.00

639.00

661.00

641.00

Fresenius SE KGaA Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Research & Development	Get a 7-Day Free Trial															139.00	155.00	170.00	177.00	140.00

Fresenius SE KGaA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €642 Mil.

Fresenius SE KGaA (XTER:FRE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Fresenius SE KGaA Research & Development Related Terms

Thank you for viewing the detailed overview of Fresenius SE KGaA's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresenius SE KGaA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius SE & Co KGaA (XTER:FRE) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

FSNUY:USA FSNUF:USA 1FRE:Italy FREd:UK 0OO9:UK FRE:Austria

Address

Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352

Website

https://www.fresenius.com

Fresenius SE is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.

Executives

Sara Hennicken	Board of Directors
Michael Sen	Board of Directors
Robert Möller	Board of Directors
Pierluigi Antonelli	Board of Directors
Dr. Frank Appel	Supervisory Board
Dr. Michael Moser	Board of Directors
Dr. Francesco De Meo	Board of Directors
Stephan Sturm	Board of Directors
Wolfgang Kirsch	Supervisory Board
Mats Henriksson	Board of Directors
Dr. Gerd Krick	Supervisory Board

Fresenius SE KGaA Headlines

No Headlines